A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer

Overview of attention for article published in European Journal of Cancer (1965), April 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (83rd percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

policy: 2 policy sources

twitter: 4 X users

Readers on

mendeley: 61 Mendeley

Summary Policy documents X

So far, Altmetric has seen 3 policy documents that reference this research output.

Opdivo for Non-Small Cell Lung Cancer – Details

Cited by Canadian Agency for Drugs and Technologies in Health on 01 Jun 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Nivolumab for previously treated non-squamous non-small-cell lung cancer: Committee papers

Cited by National Institute for Health and Care Excellence on 05 May 2016

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Lung cancer: diagnosis and management: Appendix A: Decision matrix

Cited by National Institute for Health and Care Excellence on 17 Mar 2016

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.